Search
Searching Content indexed under Life Sciences, Biotechnology & Nanotechnology by Morrison & Foerster LLP ordered by Published Date Descending.
Links to Result pages
 
1 2 3 4  
>>Next
 
Title
Country
Organisation
Author
Date
1
Morrison & Foerster Launches Complimentary Tracker For Northern District Of California IP Cases
We are pleased to announce the launch of the MoFo NDCal IP Resource Center. This complimentary resource is available to the public and provides insights on the judges
United States
16 Sep 2019
2
Meet MoFo's Diverse IP Litigators: Mary Prendergast
Mary Prendergast is an associate in MoFo's Washington, D.C. office. Her practice focuses on intellectual property and commercial litigation
United States
1 Aug 2019
3
Meet MoFo's Diverse IP Litigators: Chanwoo Park
Chanwoo Park is an associate in MoFo's New York office. His practice focuses on intellectual property litigation, including patent, trade secret, and copyright
United States
1 Aug 2019
4
Committed To Clarity: FDA's Dedication To Transparency With The End Of ASR
On June 21, the Food and Drug Administration (FDA) released a report titled "Statement on agency's efforts to increase transparency in medical device reporting."
United States
15 Jul 2019
5
What Are The Top Hatch-Waxman And BPCIA Developments For November 2018?
This month we highlight two reversals by the Federal Circuit and a summary judgment of indefiniteness from New Jersey.
United States
14 Dec 2018
6
新的CFIUS试点计划:生命科学公司和投资者须知
如许多生命科学公司和投资者所知,美国财政部("财政部")最近对美国外国投资委员会("CFIUS")公布了一项新的"试点计划",
China
15 Nov 2018
7
What Are The Top Hatch-Waxman And BPCIA Developments For October 2018?
This month we highlight a new law requiring notification to the Federal Trade Commission and Department of Justice of biosimilar litigation settlements and perhaps the end of a long-running Mylan venue dispute in Delaware.
United States
9 Nov 2018
8
New CFIUS Pilot Program: What Life Sciences Companies And Investors Need To Know
As many life sciences companies and investors are aware, the U.S. Department of the Treasury ("Treasury") recently announced a new "pilot program" for the Committee on Foreign Investment...
United States
5 Nov 2018
9
What Are The Top Hatch-Waxman And BPCIA Developments For September 2018?
This month we highlight the possibility that the Supreme Court will consider the standard for adequacy of written description and a Federal Circuit exposition on the relationship between "blocking patents" and objective indicia of nonobviousness.
United States
19 Oct 2018
10
What Are The Top Hatch-Waxman And BPCIA Developments For July 2018?
This month, we highlight significant developments from July 2018, including the FDA's Biosimilar Action Plan for "reducing gaming of FDA requirements or other attempts to unfairly delay competition" ...
United States
28 Aug 2018
11
CJEU Raises Bar For Use Of CRISPR In Europe's Agribusiness: What You Need To Know
Today, the CJEU has issued its much awaited decision on the classification of genome-editing tools such as CRISPR/Cas9, Talen or zinc finger within the framework of the EU's Directive 2001/18/EC...
European Union
2 Aug 2018
12
3D Printing Meets Medical Devices: FDA Weighs In On Additive Manufacturing
In December, the U.S. Food and Drug Administration (FDA) issued guidance on Technical Considerations for Additive Manufactured Medical Devices.
United States
17 Jan 2018
13
More On The U.S. IPO Market
As previously reported, the U.S. markets have experienced a 35% year-over-year increase in volume, with 111 IPOs completed in the first nine months of 2017, raising $26.5 billion.
United States
20 Oct 2017
14
Cancer Moonshot: USPTO Extends Cancer Immunotherapy Pilot Program Initiative
The United States Patent and Trademark Office (PTO) issued a Notice today extending the Cancer Immunotherapy Pilot Program (Pilot Program), also known as "Patents 4 Patients."
United States
3 Jul 2017
15
New Regulations On Clinical Research
On April 7, 2017, the 193rd Diet of Japan passed a legislation regarding clinical researches – this "Law on Clinical Research (rinsho kenkyu hou)" will come into effect within one year.
Japan
19 May 2017
16
Late Stage Private Placements: A Life Sciences Sector Survey
As many privately held companies choose to remain private longer and defer their initial public offerings, these companies are increasingly reliant on raising capital in successive private placements.
United States
12 May 2017
17
2016 Biometer Shows Strength In Early And Late Stage Deals But Cracks Beneath The Surface
The 2016 BioMeter showed strength at both ends of the drug-development spectrum, with extremely strong results for pre-clinical/discovery transactions and approved product transactions.
United States
7 Apr 2017
18
Expanding Duties And Eroding Protections For Medical Device Manufacturers
This decision comes as a surprise and represents an unexpected shift in the law with regard to medical device manufacturers.
United States
2 Mar 2017
19
FDA (Finally!) Issues New Regulations To Clarify Pharmaceutical Patent Litigation: How To Use Patent "Use Codes"
On October 6, 2016, the FDA issued a final rule implementing certain provisions of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) governing the approval of generic drugs...
United States
19 Oct 2016
20
Late-Stage Private Placements: A Life Sciences Sector Survey
As privately held companies choose to remain private longer and defer their initial public offerings (IPOs), these companies are increasingly reliant on raising capital in successive private placements.
United States
29 Jul 2016
Links to Result pages
 
1 2 3 4  
>>Next